Inclusion Criteria:

          -  Female and male subjects ≥18 years of age with one of the following:

               -  Relapsed or refractory acute myelocytic leukemia (AML) with nucleophosmin-1
                  (NPM1) mutations and no available therapies.

               -  Relapsed or refractory acute promyelocytic leukemia (APL), with no available
                  therapies. Note: Prior exposure to arsenic trioxide is allowed; however, subjects
                  who have failed arsenic trioxide within the last 12 months are not allowed.

               -  Relapsed or refractory myelodysplastic syndrome (MDS), International Prognostic
                  Scoring System intermediate or high-risk, with no available therapies

               -  Relapsed or refractory chronic myelomonocytic leukemia (CMML), and other
                  MDS/myeloproliferative neoplasm (MPN) overlap syndromes, with no available
                  therapies

               -  Relapsed or refractory mantle cell lymphoma (MCL) with no adequate therapies.

          -  Negative pregnancy test at the Screening visit for women of childbearing potential and
             willingness to use adequate birth control

          -  Not willing to undergo, not a candidate for, or not having a donor for immediate
             (within 3 months from the Screening date) bone marrow transplantation.

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status of ≥3;

          -  Absolute myeloblast count ≥20,000/mm^3;

          -  Administration of any antineoplastic therapy within 5 half-lives of the antineoplastic
             therapy before the first dose of ORH-2014, with the exception of hydroxyurea that
             should be discontinued 1 day prior to the first dose of ORH-2014

          -  Presence of any remaining toxicities due to previous chemotherapy

          -  Participation in other clinical trials within at least 2 weeks of the first ORH-2014
             dose;

          -  Clinical evidence of active central nervous system leukemia;

          -  Active and uncontrolled infection

          -  Major surgery within 2 weeks prior to trial entry;

          -  Liver function tests above the following limits at Screening: total bilirubin >1.5 x
             upper limit of normal (ULN) unless related to Gilbert's syndrome or hemolysis;
             aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x ULN; for
             subjects with liver involvement, AST and/or ALT >5 x ULN;

          -  Serum creatinine >1.5 x ULN and/or creatinine clearance or estimated glomerular
             filtration rate <30 mL/min

          -  Impaired cardiac function

          -  Myocardial infarction of unstable angina within 6 months prior to the planned start
             date of study drug.